[Edaily Reporter Kwon Oh Seok ] MedPacto, Inc.(235980)announced on the 18th that it has submitted an application to the U.S. Food and Drug Administration (FDA) for approval of an amendment to its Investigational New Drug (IND) application for a Phase 1/2 clinical trial of Bactosetip monotherapy in patients with recurrent, refractory, or progressive osteosarcoma.
Disclosure Plus
MedPacto, Inc. Submits Application to U.S. FDA for Approval of Amended Phase 1 and 2 Clinical Trial Protocol for Baektoxetip Monotherapy
Kwon Oh Seok
2026-09-18 18:07:35
Economy
Corporation
IT·Science
Economy
[VC's Pick] Riding the Wave of South Korea’s Defense Industry Boom, Digitron Sets Sights on IPO… Secures Pre-IPO Investment
This week (October 6–8), startups across various sectors—including defense, biotech, and artificial intelligence (AI) image-generation platforms—secured investments from venture capital (VC) firms and…
Corporation
Choi Tae-won: “For the Honam Semiconductor Project, Construction Will Begin First Even If Power and Water Supply Are Delayed… Scale Will Be Two-Thirds That of Yongin” (Comprehensive)
SK Group Chairman Choi Tae-won announced plans to establish a semiconductor production hub in the Honam region that would be two-thirds the size of the Yongin Semiconductor Cluster. He also left open …
IT·Science
A Star at a Park That Attracted 1 Million Visitors… But What to Do About the Injured “Bukang-i”?
“Bukangi,” the black shark that has been residing in the artificial waterway at Busan’s North Port Waterfront Park and has attracted over 1 million visitors. It appears that more people believe the go…
